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Castleman’s disease is rare lymphoproliferative disorder that typically presents as a mediastinal mass,
although 10% of cases may be intra-abdominal. Given its rarity, diagnosis is often delayed until other
pathology has been ruled out. We present the case of a 15-year-old boy with a one-year history of
progressive fatigue, failure to thrive, and severe iron resistant, iron deﬁciency anemia. Extensive work-up
revealed an intra-abdominal mass. At laparotomy, a discrete lymphoid-appearing mass was found at the
base of the mesentery. Excision led to rapid and complete resolution of his symptoms, including reso-
lution of anemia. Pathology demonstrated Castleman’s disease of the hyaline vascular subtype. Increased
awareness of this entity and its association with severe iron deﬁciency anemia though the over-
production of IL-6 may allow earlier detection and treatment.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Castleman’s disease is an uncommon lymphoproliferative dis-
order that may present with B-symptoms, failure to thrive, rashes,
hepatosplenomegaly, and anemia.We present the case of a 15-year-
old boy with Castleman’s disease who presented with severe iron
deﬁciency anemia refractory to oral iron replacement therapy.
A literature review is presented reviewing the pathogenesis of
Castleman’s disease and its association with IL-6 and hepcidin
induced iron deﬁciency anemia.1. Case report
A 15-year-old boy was referred to the Children’s Hospital at
London Health Science Center (LHSC) with a history of severe iron
deﬁciency anemia unresponsive to oral iron replacement therapy.
Two months previously he had presented to his community
pediatrician complaining of fatigue. He was diagnosed with iron
deﬁciency anemia and started on oral iron replacement therapy.
He subsequently presented to his local emergency department
with testicular pain diagnosed as orchitis. During assessment,
bloodwork revealed a hypochromic microcytic anemia with a he-
moglobin of 68 g/L despite 2 months of oral iron therapy. Thegery, Children’s Hospital at
00 Commissioners Rd. East,
1 519 685 8401; fax: þ1 519
rtin).
 Inc. Open access under CC BY-NC-NDpatient was transferred our Children’s Hospital for further inpa-
tient work-up.
At the time of referral, the patient reported signiﬁcant failure to
thrivewith less than 2 kg of weight gained over the past 6 years and
a current weight of only 29 kg. This was accompanied by progres-
sive fatigue, anorexia, pallor and exertional dyspnea over the past
year. No other symptoms were reported including no gastrointes-
tinal symptoms or blood loss.
On physical exam the patient was noted to have chronic low-
grade fevers. He was pale and quite thin weighing in below the 3rd
percentile for age, with a BMI of 14.9 and tanner stage 2 pubertal
development. No lymphadenopathy or other anomalieswere noted.
Laboratory investigations revealed a hypochromic microcytic
anemia with a hemoglobin of 68 g/L. White blood cell count was
normal at 6.9/L with elevated platelets of 548/L. Serum ironwas low
at 3 umol/L. ESR and CRP were abnormally high at 101 mm/h and
161 mg/L respectively, while albumin was low at 28 g/L with a pre-
albumin of <0.07 mg/dL. Electrolytes, renal and liver function tests
were all within normal limits.
The patient was admitted to hospital for inpatient assessment by
the general pediatrics team. Consultationsweremade to hematology,
oncology, endocrinology, rheumatology, infectious disease, psychia-
try, and gastroenterology. An extensive work-up followed and 2
courses of intravenous iron were administered with mild improve-
ment in his hemoglobin to 73 g/L. Upper endoscopy and colonoscopy
failed to identify any gastrointestinal blood loss or other diseases.
Subsequently the patient underwent magnetic resonance enter-
ography (MRE) and capsule endoscopy to assess for small bowel le-
sions. MRE revealed a homogenous ovoid mesenteric mass (Fig. 1). license.
Fig. 1. MRE demonstrating an enlarged mesenteric lymph node [arrow] representing
an intra-abdominal focus of Castleman’s disease in a 15 year-old boy.
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laparotomy a discrete 4 cm lymphoid-appearing mass was found at
the base of the mesentery (Fig. 2). The mass was removed without
complication and no other abnormalities were found. Pathology
revealed Castleman’s disease of the hyaline vascular subtype. His
post-operative course was unremarkable. Ten weeks following
surgery, his appetite had normalized and he had gained 7 kg with a
54 g/L increases in his hemoglobin to 127 g/L.2. Discussion
Castleman’s disease, ﬁrst described by Dr. Benjamin Castleman
in 1954, represents a rare lymphoproliferative disorder with a
diverse clinical spectrum [1,2]. Mediastinal involvement is the most
common disease site but any lymph node basin may be involved.
10% of cases are intra-abdominal [1,3].
Two clinical presentations predominate: unicentric and multi-
centric. Unicentric disease comprises two-thirds of cases, with the
remainder being multicentric. Unicentric disease is usually of the
hyaline vascular subtype and often remains asymptomatic until
detected incidentally during thework-upof othermedical conditions.
In contrast, multicentric disease is usually plasmacytic or mixed
cellularity variant and typically presents with a wide range of non-
speciﬁc symptoms includingB-symptoms (fever,night sweats,weight
loss), fatigue, anorexia, rashes, anemia, thrombocytopenia, andFig. 2. Operative photo of an enlarged, 4 cm, mesenteric lymph node [arrow] in a 15
year-old boy. Pathology revealed hyaline vascular Castleman’s disease.hepatosplenomegaly [1,4]. Studies have shown that symptoms
correlate with the histological variant: patients with plasmacytic or
mixedcellularitydisease tendtobecomesymptomaticwhile systemic
symptoms in patients with hyaline vascular disease are rare [1e5].
Interestingly, our patient had unicentric hyaline vascular disease yet
presented with an array of systemic symptoms including failure to
thrive and iron deﬁciency anemia unresponsive to iron therapy.
Interleukin 6 (IL-6) is a pro-inﬂammatory cytokine implicated in
the pathogenesis of Castleman’s disease. Studies show over
expression of IL-6 in the hyperplastic lymph nodes affected by Cas-
tleman’s disease [1,5]. Furthermore, animal models demonstrating
over-expression of IL-6 reproduce the phenotype of Castleman’s
disease, while blockage of IL-6 leads to symptom resolution [2]. IL-6
over-expression is thought to mediate the iron deﬁciency anemia
seen in Castleman’s disease through regulation of hepcidin [4].
Hepcidin is a regulator of iron homeostasis. It mediates iron
metabolism through the inhibitionof intestinal absorptionof ironand
blocking iron release frommacrophages and hepatocytes [4]. Hepatic
production of hepcidin is stimulated by IL-6. Over-expression of IL-6
by hyperplastic lymph nodes in Castleman’s disease creates a chronic
inﬂammatory state anddrives the over-expression of hepcidin,which
in turn inhibits intestinal absorption of iron, resulting in an iron
deﬁciency anemia refractory to oral iron replacement therapy [1,4,5].
Our patient underwent inpatient assessment with multiple
consultations and investigations prior to an MRE that ﬁnally
demonstrated the enlarged, mesenteric lymph node that ultimately
lead to his diagnosis of Castleman’s disease. The primary care team
was puzzled by the degree of anemia and it’s refractory nature.
Increased awareness of the association between B-symptoms, fail-
ure to thrive and refractory iron deﬁciency anemia may have
pointed toward Castleman’s disease earlier in the course of inves-
tigation and limited the morbidity associated with prolonged hos-
pitalization and an extensive diagnostic work-up.
Unicentric disease carries an excellent prognosis with complete
resolution of symptoms in over 90% of cases following treatment
[2]. Surgical excision is the treatment of choice for unicentric
disease, however location may prevent excision. Radiation therapy
is considered second line. There is no standard treatment of
multicentric disease. Options include steroids, thalidomide,
cyclophosphamide, vinblastine, rituximab, radiation, or bone
marrow transplantation [1,3]. Surgical debulking has been used in
the past. Debulking provides a degree of symptom control but is
not curative and has been largely replaced by medical manage-
ment [1]. Tocilizumab, an anti-IL-6 receptor antibody, has shown
promising results in the treatment of Castleman’s disease [2e5].
Studies have shown that Tocilizumab decreases IL-6 binding
leading to symptom resolution in both adult and pediatric pop-
ulations [5,6]. Speciﬁcally Tocilizumab is thought to decrease
hepcidin levels through the IL-6 pathway and thus be effective
against the associated iron deﬁciency anemia [4].
3. Conclusion
Castleman’s disease is a rare lymphoproliferative disorder that
can cause a variety of insidious and progressive symptoms.
Awareness of this disease entity can lead to earlier diagnosis and
treatment limiting associated morbidity.
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